CLDX
Celldex Therapeutics Inc
33.50$
-11.6%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2,831.5% | -1,804.5% | -1,665.7% | -784.2% | -788.8% | -1,299.0% | -544.7% | -1,309.6% | -4,401.0% | -1,558.8% | -2,247.5% | -14,063.0% | |
| 94.8% | 73.2% | 60.3% | 41.7% | 39.9% | 136.0% | 53.0% | 66.0% | 59.4% | 43.7% | 45.3% | -165.0% | |
| 191.1% | 233.1% | 225.7% | 96.6% | 84.7% | 127.4% | 52.8% | 192.5% | 662.3% | 347.1% | 487.8% | 2,414.5% | |
| 190.9% | 233.1% | 226.9% | 2.2% | 928.6% | 141.8% | 212.3% | 163.1% | 407.1% | – | – | – | |
| 170.9% | 198.7% | -96.7% | -95.8% | -161.2% | -121.0% | -4.0% | -22.7% | -165.4% | 195.6% | -307.7% | 937.2% | |
| 53.8% | 89.0% | 40.5% | 14.0% | 8.5% | 20.5% | 20.9% | 26.9% | 77.6% | 26.4% | 27.3% | 180.9% | |
| -1,143.6% | -915.9% | 1,015.4% | 364.7% | 312.6% | 478.0% | -1,324.0% | -4,647.5% | 3,816.0% | -1,536.9% | -4,132.9% | 13,938.1% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 32.7% | 3,524.7% | 213.4% | 402.5% | 308.7% | 455.0% | 2,308.3% | 5,856.2% | – | – | – | – | |
| – | – | – | – | – | – | – | 0.0% | 0.0% | – | – | – | |
| 32.7% | 3,524.7% | 213.4% | 402.5% | 308.7% | 455.0% | 2,308.3% | 5,856.2% | 172.9% | 3,173.9% | 6,288.4% | 159.2% | |
| -3,942.6% | 804.5% | -436.9% | -17.1% | -167.5% | -366.0% | 439.5% | -100.9% | -412.1% | 78.2% | -92.0% | 34.3% | |
| -2,885.3% | -1,893.5% | -1,706.3% | -798.2% | -797.3% | -1,319.5% | -565.6% | -1,336.4% | -4,478.6% | -1,585.2% | -2,274.9% | -14,243.9% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.